News

Fineotex Chemical Limited announced that its wholly-owned subsidiary, Fineotex Biotex HealthGuard FZE, has incorporated a new wholly-owned step-down subsidiary, Fineotex Holdings Inc., in the USA, with 100% share capital held by Fineotex Biotex HealthGuard FZE. The new entity, Fineotex Holdings Inc., incorporated in the State of Delaware, USA, will undertake specialty chemical and allied business activities, including manufacturing, trading, and development, and pursue strategic investments and acquisitions.

Fineotex Chemical Limited has set Friday, September 04, 2026, as the cut-off date for remote e-voting and the record date for determining members eligible to receive the final dividend for the financial year 2025-26, according to a regulatory filing. The company’s 23rd Annual General Meeting will be held on Friday, September 11, 2026, at 4:00 P.M. (IST) via video conferencing or other audio visual means.

Fineotex Chemical Limited informed the Bombay Stock Exchange and the National Stock Exchange of India that its Board of Directors approved holding the 23rd Annual General Meeting on Friday, September 11, 2026, at 4:00 P.M. (IST) through video conferencing or other audio-visual means, with a record date for the meeting and final dividend payment fixed as Friday, September 4, 2026, and approved a proposal to raise funds through equity shares or other equity-linked securities, subject to member and regulatory approvals.

Fineotex Chemical Limited informed the Bombay Stock Exchange and the National Stock Exchange of India that its Board of Directors approved holding the 23rd Annual General Meeting on Friday, September 11, 2026, at 4:00 P.M. (IST) through video conferencing or other audio-visual means, with a record date of Friday, September 4, 2026, for dividend eligibility, and also approved a proposal to raise funds through the issuance of equity shares and/or other equity-linked securities.

Fineotex Chemical Limited will hold a board meeting on August 17, 2026, to consider a proposal for raising funds through the issuance of equity shares and/or other equity-linked securities via methods including private placement, preferential issue, qualified institutions placement, further public offer, or a combination thereof, subject to shareholder and regulatory approvals.